Hospital Universitario Fundacion Jimenez Diaz
Hospital Universitario Fundacion Jimenez Diaz is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKD
Sponsor Rocket Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Non‐Randomized, Open‐Label, Prospective Phase II Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment. STROBE
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer treated with Neratinib plus Loperamide prophylaxis versus Neratinib with Initial Dose Escalation plus PRN Loperamide prophylaxis versus Neratinib plus Loperamide plus Colesevelam prophylaxis. “DIANER Study”
Sponsor Fundacion Grupo Espanol De Investigacion En Cancer De Mama
- Start (EU)
- Latest update
- Estimated end
- Not reported
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study”
Sponsor Fundacion Grupo Espanol De Investigacion En Cancer De Mama
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in combination with PD-0332991 (Palbociclib) as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and remained disease free for more than 12 months following its completion or have de novo metastatic disease. "The FLIPPER Study"
Sponsor Fundacion Grupo Espanol De Investigacion En Cancer De Mama
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET Study”
Sponsor Fundacion Grupo Espanol De Investigacion En Cancer De Mama
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients “CARABELA Study”
Sponsor Fundacion Grupo Espanol De Investigacion En Cancer De Mama
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Hospital Universitario Fundacion Jimenez Diaz?
The 2026-10-09 snapshot links Hospital Universitario Fundacion Jimenez Diaz to 8 distinct CTIS trials. Recorded services include Laboratory services, Hart and Liver MRI, To perform real-time polymerase chain reaction (PCR) test for the detection of PIK3CA mutations. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Hospital Universitario Fundacion Jimenez Diaz?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Hospital Universitario Fundacion Jimenez Diaz conducted?
The linked trials record locations in 8 countries, including Spain, France, Italy, Germany, Denmark. These are trial locations, not confirmed office locations or countries where Hospital Universitario Fundacion Jimenez Diaz delivered services.
What can this page tell me about Hospital Universitario Fundacion Jimenez Diaz's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Hospital Universitario Fundacion Jimenez Diaz. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Hospital Universitario Fundacion Jimenez Diaz